Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

NCT04236219 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT04236219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04236219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
September 2, 2020
Completion date
November 6, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia